Search results
Added:
5 months ago
Prof Chim Lang discusses his upcoming special focus for ECR. The collection will include contributions from Dr Emily Morris, Dr John Wilding, Dr Samira Bell, Dr Bianca Rocca, and Dr Ramzi Ajjan, the collection explores the global burden of obesity, its impact on heart failure and kidney disease, and emerging therapeutic strategies—including the evolving role of GLP-1 receptor agonists.
View more
Added:
3 weeks ago
AHA Scientific Sessions 2025 – Dr Anna Meta Dyrvig Kristensen (Copenhagen University Hospital, Bispebjerg and Frederiksberg, DK) presents an individual patient data meta-analysis examining beta-blocker therapy after myocardial infarction in patients with preserved left ventricular ejection fraction.This comprehensive meta-analysis pooled individual patient data from five randomized controlled…
View more
Added:
1 month ago
AHA Scientific Sessions 2025 - Phase 1 results show the CRISPR-Cas9 gene editing therapy is a safe treatment option targeting ANGPTL3 in patients with lipid disorders.Prof Stephen Nicholls (Monash Victorian Heart Institute, Clayton, AU) joins us to share results from a first-in-human phase 1 trial investigating a one-time infusion of CTX310, a CRISPR-Cas9 gene editing therapy, at different doses…
View more
Added:
2 months ago
Added:
1 year ago
Added:
2 months ago
Learn about the definition and implications of a shock diagnosis and systems of care and the role of the shock team from Dr Frederick Welt (University of Utah, US).This three-part video lecture series, part of Women As One’s CLIMB® 2025 Skills Training Programme, offers case-based insights into Coronary and Mechanical Support for Cardiogenic Shock, curated by Dr Alison Duncan and Dr Frederick…
View more
Added:
1 year ago
ECO 2024 — Dr Riccardo Panella (Aalborg University, DK) joins us to discuss a ncRNA-based approach in treating obesity. This new combinatory treatment (Resalis) aims to increase GLP1-RA efficacy by targeting non-coding RNA.Questions1. What is the background of this combinatory approach?2. What data did you present at ERA 24?3. What are the challenges and opportunities in approaching combinatory…
View more
Added:
1 year ago
Dr Luca Testa (IRCCS Policlinico San Donato, IT) discusses the results of the XLIMIT Trial at the EuroPCR 2024 congress in Paris, France.In this video interview, Dr Testa explains the technology behind the XLIMUS® drug-eluting stent (Cardionovum®) and its benefits. He also reviews the XLIMIT Trial, detailing the study design, selection criteria and clinical outcomes.Specifically, the 6 to 9…
View more
Added:
3 months ago
ESC Congress 2025 - Dr Muthiah Vaduganathan (Brigham and Women’s Hospital, Boston, US) joins us to discuss findings from a trial investigating the lifetime benefits of combination therapy for patients with HFpEF by looking at individual level data from DELIVER, FINEARTS-HF and PARAGON-HF trials.Interview Questions:1. What is the reasoning behind the trial?2. What was the study design and patient…
View more
Added:
3 months ago